Immunoglobulin G: all 31 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis BullosaRecruitingNCT06834035Phase 1/2
- A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)RecruitingNCT06747351Phase 3
- A Study of TAK-881 and HyQvia in Healthy AdultsCompletedNCT06895967Phase 1Results posted
- A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult ParticipantsCompletedNCT04578535Phase 1Results posted
- A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedNCT04424641Phase 1/2Results posted
- Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD SubjectsCompletedNCT03277313Phase 3Results posted
- Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD SubjectsCompletedNCT03116347Phase 4Results posted
- Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPCompletedNCT02955355Phase 3Results posted
- Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) NeuropathyCompletedNCT02638207Phase 3Results posted
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT02549170Phase 3Results posted
- Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune ThrombocytopeniaCompletedNCT01349790Phase 3Results posted
- High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)CompletedNCT01313507Phase 3Results posted
- Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive ImpairmentCompletedNCT01300728Phase 2Results posted
- A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency DiseasesCompletedNCT01012323Phase 3Results posted
- IVIG Versus Placebo for the Treatment of Patients With Severe C-DiffTerminatedNCT00177970Phase 4Results posted
- A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection ConditionsCompletedNCT07025577Phase 1
- Phase III Clinical Study of NPB-01 in Patients With Autoimmune EncephalitisStatus unknownNCT05177939Phase 3
- Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:CompletedNCT04175522Phase 2
- Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's DiseaseCompletedNCT03008161Phase 1
- Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)CompletedNCT02556437Phase 2
- A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody DeficiencyCompletedNCT02247154Phase 4
- Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeCompletedNCT02221271Phase 3
- Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.CompletedNCT01845584Phase 2
- Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.CompletedNCT01827072Phase 3
- Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.CompletedNCT01824251Phase 3
- Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki DiseaseCompletedNCT01524939Phase 4
- Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to CorticosteroidsCompletedNCT01408550Phase 3
- GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic ShockTerminatedNCT01315496Phase 3
- Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPTerminatedNCT01225276Phase 2/3
- Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.CompletedNCT00809822Phase 2
- Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary ImmunodeficiencyCompletedNCT00680446Phase 3